^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Follow It®

Type:
Laboratory Developed Test
Related tests:
Evidence

News

1year
Liquid biopsy testing in metastatic or advanced breast cancer patients during the COVID-19 pandemic (AACR 2023)
A population of Canadian women with metastatic breast cancer were tested using a liquid biopsy gene panel during the COVID-19 pandemic for identification of biomarkers for targeted therapeutic options. Over 50% of the samples were identified as hormone positive, with greater than 60% harboring PIK3CA and ESR1 ctDNA mutations. Studies have shown that metastatic PIK3CA mutated ER-positive/HER2-negative tumors are predictive to respond to alpelisib therapy and have FDA and Health Canada approval.
Clinical • Liquid biopsy • Metastases • Biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
HER-2 positive • TP53 mutation • ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative
|
Follow It®
|
Piqray (alpelisib)
over1year
DelPHI: Delivering Precision Health Insights for Timely Treatment of Rhabdomyosarcoma Using Protean MAPS and NAVIFY Digital Tools (AMP 2022)
By combining multiple types of molecular analyses, it was uncovered that this patient was eligible for novel clinical trials containing MEK and PD-L1 checkpoint inhibitors. Digital tools for genomic interpretation, clinical trials matching, and molecular tumor board discussions not only provided clinical decision support but also accelerated the path to treatment options.
PD(L)-1 Biomarker • IO biomarker
|
NRAS (Neuroblastoma RAS viral oncogene homolog)
|
NRAS mutation • NRAS Q61K • NRAS Q61
|
Follow It® • OncoSignal™
almost2years
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease (clinicaltrials.gov)
P=N/A; Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jul 2022
Enrollment open • Trial initiation date • Liquid biopsy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Follow It®
almost2years
eDetect-mCRC: Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
P=N/A; Not yet recruiting --> Recruiting | Initiation date: Oct 2021 --> Jun 2022
Enrollment open • Trial initiation date
|
Follow It®
2years
Embryonal rhabdomyosarcoma in a pediatric patient: Therapeutic target identification (Protean BioDiagnostics Press Release)
"Protean BioDiagnostics to present on embryonal rhabdomyosarcoma in a pediatric patient...Combining immunohistochemistry, OncoTargets pathway analysis that measures key signaling pathway activity, Follow It liquid biopsy, and structural chromosome aberration analysis by copy number variation uncovered that this patient was eligible for a novel clinical trial containing MEK and PD-L1 checkpoint inhibitors."
Clinical data
|
Follow It®
2years
CASE OF AN EMBRYONAL RHABDOMYOSARCOMA IN A PEDIATRIC PATIENT: THERAPEUTIC TARGET IDENTIFICATION (ASPHO 2022)
The analyses revealed important takeaways: 1) key activating mutations can be identified using a simple liquid biopsy, 2) some embryonal RMS cases have PD-L1 expression, and 3) OncoSignal analysis may be useful in identifying oncogenic driver pathways. These findings helped to identify that this child was eligible for a clinical trial that contained combined MEK and PD-L1 checkpoint inhibitors, a potential solution to treating embryonal RMS.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • FGFR4 (Fibroblast growth factor receptor 4) • PAX3 (Paired Box 3) • PAX7 (Paired Box 7)
|
PD-L1 expression • TP53 mutation • KRAS mutation • NRAS mutation • PIK3CA mutation • EGFR amplification • NRAS Q61K • NRAS Q61 • KRAS Q61K
|
Follow It® • OncoSignal™
2years
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease (clinicaltrials.gov)
P=N/A; N=10; Not yet recruiting; Sponsor:British Columbia Cancer Agency
New trial • Liquid biopsy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Follow It®
over2years
Accelerating Lung Cancer Diagnosis and Molecular Profiling through Liquid Biopsy (IASLC-TTLC 2022)
Median time from referral to treatment initiation was 31 days (range 16-41) if an actionable alteration was identified in plasma versus 35 days if none was identified (range 20-58).Conclusion While liquid biopsy in the initial diagnostic workup of advanced NSCLC patients may accelerate profiling Result s and treatment initiation, comprehensive NGS assays with faster TAT are needed. An expansion study (N=150) is ongoing with a comprehensive DNA-based assay with faster TAT (SNV, indels, fusions, CNV; InVisionFirst, Inivata).
Liquid biopsy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase)
|
Oncomine™ Comprehensive Assay v3M • InVisionFirst®-Lung • Follow It®